Boron neutron capture therapy for malignant melanoma： first clinical case report in China

A phase Ⅰ/Ⅱ clinical trial for treating malignant melanoma by boron neutron capture therapy（BNCT） was designed to evaluate whether the world＇s first in-hospital neutron irradiator（IHNI） was qualified for BNCT. In this clinical trial planning to enroll 30 patients, the first case was treated on August 19, 2014. We present the protocol of this clinical trial, the treating procedure, and the clinical outcome of this first case. Only grade 2 acute radiation injury was observed during the first four weeks after BNCT and the injury healed after treatment. No late radiation injury was found during the 24-month follow-up. Based on positron emission tomography-computed tomography（PET/CT） scan, pathological analysis and gross examination, the patient showed a complete response to BNCT,indicating that BNCT is a potent therapy against malignant melanoma and IHNI has the potential to enable the delivery of BNCT in hospitals.

医院中子照射器建造

医院中子照射器装置于2007年开始建造,2008年12月完成了反应堆厂房建造,2009年3月完成了相关系统的安装和调试。2009年12月7日首次达到临界,2010年1月22日达到满功率运行。物理调试结果表明,医院中子照射器反应堆最终后备反应性为4.2 mk,满功率最大可连续运行时间为12 h,功率波动小于0.3%;4.2 mk反应性释放实验表明,反应堆在229 s时达到85.7 kW的最大峰值功率,随后,由于燃料元件多普勒效应和慢化剂的负温度效应会非能动地把功率限制在允许的安全水平之下,反应堆具有良好的固有安全特性。